NEUCHATEL, Switzerland--(BUSINESS WIRE)--Masimo (NASDAQ: MASI) announced today the CE marking of Next Generation SedLine ® brain function monitoring for pediatric patients (1-18 years of age). With ...
Masimo Corporation MASI recently received the FDA’s clearance for SedLine brain function monitoring for pediatric patients (1-17 years of age) and the SedLine Pediatric EEG (electroencephalogram) ...
Masimo Corporation MASI recently announced the findings of a prospective study published in Frontiers in Neurology. The study evaluated whether general anesthesia guided by Masimo SedLine Brain ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback